These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19001346)

  • 1. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
    Wong R; Cunningham D
    J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
    [No Abstract]   [Full Text] [Related]  

  • 2. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
    Hawkes E; Cunningham D
    J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
    [No Abstract]   [Full Text] [Related]  

  • 4. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
    Bertagnolli MM
    J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
    [No Abstract]   [Full Text] [Related]  

  • 5. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
    Hawkes E; Cunningham D
    Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR FISH in colorectal cancer: what is the current reality?
    Moroni M; Sartore-Bianchi A; Veronese S; Siena S
    Lancet Oncol; 2008 May; 9(5):402-3. PubMed ID: 18452847
    [No Abstract]   [Full Text] [Related]  

  • 9. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
    de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
    J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
    [No Abstract]   [Full Text] [Related]  

  • 10. EGFR antibodies in colorectal cancer: where do they belong?
    Grothey A
    J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
    [No Abstract]   [Full Text] [Related]  

  • 11. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
    Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
    J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
    [No Abstract]   [Full Text] [Related]  

  • 13. [Biology applied to cancer treatments: the example of colorectal cancer].
    Lièvre A; Laurent-Puig P
    Rev Prat; 2010 Oct; 60(8):1100-2. PubMed ID: 21197742
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy and immunotherapy in metastatic colorectal cancer.
    Loupakis F; Di Maio M; Falcone A
    N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445032
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A; Siena S
    J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF testing in advanced colorectal cancer: is it ready for prime time?
    Phillips B; Kalady M; Kim R
    Clin Adv Hematol Oncol; 2010 Jun; 8(6):437-44. PubMed ID: 20733556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
    Katsios C; Ziogas DE; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):525-9. PubMed ID: 20932136
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutation screening for KRAS and BRAF in metastatic colorectal cancer proves costly in relation to benefits.
    Pharmacogenomics; 2013 Jan; 14(2):124. PubMed ID: 23447823
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
    Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.